Walvax Biotechnology Selects Medidata’s Cloud-Based Platform to Advance Pediatric Vaccine Program in China

Published on: 

Applied Clinical Trials

NEW YORK, N.Y. – September 8, 2015 – Medidata (NASDAQ: MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced that its industry-leading technology platform has been adopted by Walvax Biotechnology Co., Ltd (“Walvax”) (SZSE: 300142), a biopharmaceutical company in China. Walvax is harnessing the Medidata Clinical Cloud® platform to improve data management activities and drive biomedical innovation in the development of a pneumococcal conjugate vaccine for infants.

“Pneumococcal infections-including pneumonia, blood infections and meningitis-can be extremely difficult to treat, making prevention through vaccination a critical component of patient care,” said Yi Zhang, Vice President, Walvax. “We’re pleased to be using Medidata’s robust, globally-validated technology to bring greater speed and operational efficiencies to our pneumococcal conjugate vaccine trials, ultimately leading to a safe and effective way to ensure young children are protected from the devastating effects of pneumococcal diseases.”

Founded in 2001, Walvax Biotechnology specializes in the research, development, production and distribution of bio-medicine products, including vaccines and blood products. To optimize the execution of its novel research on a vaccine for pneumococcal conjugate (PCV13)-the first multi-center clinical trials to be conducted on infants and toddlers in China-Walvax is utilizing Medidata’s cloud-based technology for electronic data capture and management (Medidata Rave®). The Chinese biopharmaceutical company is also leveraging training available through Medidata’s professional services offering to speed study implementation and ensure trial timelines are met.


"Medidata's cloud-based platform is designed to bring efficiencies to clinical trials of all sizes and therapeutics areas," said Takeru Yamamoto, Medidata’s managing director of the Asia-Pacific (APAC) region. "We’re proud to be collaborating with Walvax as the organization advances pneumococcal conjugate vaccine research in China, resulting in better preventative treatment for young people around the world."